KLCM Advisors Inc. Sells 17,799 Shares of Bristol Myers Squibb Company $BMY

KLCM Advisors Inc. cut its position in Bristol Myers Squibb Company (NYSE:BMY) by 5.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 321,868 shares of the biopharmaceutical company’s stock after selling 17,799 shares during the period. Bristol Myers Squibb makes up about 1.4% of KLCM Advisors Inc.’s investment portfolio, making the stock its 20th largest holding. KLCM Advisors Inc.’s holdings in Bristol Myers Squibb were worth $14,516,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in BMY. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb in the 2nd quarter worth approximately $25,000. Harbor Capital Advisors Inc. boosted its stake in Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 313 shares during the last quarter. Total Investment Management Inc. purchased a new position in shares of Bristol Myers Squibb in the second quarter worth $38,000. Twin Peaks Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb during the second quarter valued at $40,000. Finally, Bank of Jackson Hole Trust increased its holdings in Bristol Myers Squibb by 352.2% in the 3rd quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 810 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Down 0.3%

NYSE:BMY opened at $59.97 on Thursday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The business has a fifty day moving average price of $58.02 and a 200-day moving average price of $51.27. The firm has a market capitalization of $122.12 billion, a price-to-earnings ratio of 17.38, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter last year, the firm posted $1.67 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 73.04%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on BMY shares. Wells Fargo & Company reaffirmed an “outperform” rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Morgan Stanley restated an “underweight” rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Scotiabank reaffirmed a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Leerink Partners boosted their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Nine equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $61.00.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.